Apple this month received approval to launch the Apple Watch's sleep apnea notifications feature in Malaysia, as noted by ...

An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available. Mineralys Therapeutics announced that the U.S. FDA ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...

Both Novo Nordisk and Eli Lilly are studying their weight loss drugs to treat fatty liver disease, chronic kidney disease, ...

Mineralys Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational ...

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced the clearance of its investigational new drug (IND) application by ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...